Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

August 27, 2018 updated by: Eisai Co., Ltd.

A Single and Multiple Dose Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

This study will be conducted to evaluate the pharmacokinetics of perampanel following single and multiple oral doses in Chinese healthy male and female participants.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
44

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China
        • Eisai Trial Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 45 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Participants must meet all of the following criteria to be included in this study:

  • Chinese healthy adult volunteers (males and females)
  • Non-smoking, male or female age ≥18 years and ≤45 years old at the time of obtaining written consent. To be considered non-smokers, participants must have discontinued smoking from screening before first dosing.
  • Participants with a Body Mass Index ≥18.5 and <24.5 kilograms per meters squared at screening
  • Participants who undergo screening within 3 weeks before study treatment and are confirmed to be eligible by the investigator

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from this study:

  • Participants who weigh less than 50 kilograms
  • Females who are breastfeeding or pregnant at Screening or Baseline
  • Females of childbearing potential
  • Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks before first dosing
  • Evidence of disease that may influence the outcome of the study within 4 weeks before first dosing
  • Any history of gastrointestinal surgery that may affect pharmacokinetic profiles of perampanel at Screening
  • Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at Screening
  • A prolonged QT/corrected QT (QTc) interval (QTc interval for heart rate using Fredericia's formula >450 milliseconds) as demonstrated by a repeated ECG at Screening or Baseline

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: Perampanel single-dose Part: 2 mg group
Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
Drug: Perampanel
Oral Tablet
Other Names:
  • E2007
EXPERIMENTAL: Perampanel single-dose Part: 4 mg group
Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
Drug: Perampanel
Oral Tablet
Other Names:
  • E2007
EXPERIMENTAL: Perampanel single-dose Part: 8 mg group
Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
Drug: Perampanel
Oral Tablet
Other Names:
  • E2007
EXPERIMENTAL: Perampanel multiple-dose Part
Participants will receive multiple oral dose of perampanel (2 milligrams per day [mg/day] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.
Drug: Perampanel
Oral Tablet
Other Names:
  • E2007

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Single-dose Part: Mean value of the maximum observed concentration (Cmax) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Single-dose Part: Mean value for the time at which the highest drug concentration occurs (tmax) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Single-dose Part: Mean value for area under the concentration-time curve from zero time to 24 hours (AUC[0-24h]) postdose of perampanel
Time Frame: 0-24 hours postdose
0-24 hours postdose
Single-dose Part: Mean value for area under the concentration-time curve from zero time to time of last quantifiable concentration (AUC[0-t]) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Single-dose Part: Mean value for area under the concentration-time curve from zero time extrapolated to infinite time (AUC[0-inf]) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Single-dose Part: Mean value for the terminal phase rate constant (λz) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Single-dose Part: Mean value for terminal elimination phase half-life (t1/2) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Single-dose Part: Mean value for apparent total clearance following oral administration (CL/F) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Single-dose Part: Mean value for the apparent volume of distribution at terminal phase (Vz/F) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Single-dose Part: Mean residence time (MRT) postdose of perampanel
Time Frame: 0-336 hours postdose
0-336 hours postdose
Multiple-dose Part: Mean value of Cmax postdose of perampanel on Day 1
Time Frame: 0-24 hours postdose on Day 1
0-24 hours postdose on Day 1
Multiple-dose Part: Mean minimum observed concentration (Cmin) postdose of perampanel on Day 1
Time Frame: 0-24 hours postdose on Day 1
0-24 hours postdose on Day 1
Multiple-dose Part: Mean tmax postdose of perampanel on Day 1
Time Frame: 0-24 hours postdose on Day 1
0-24 hours postdose on Day 1
Multiple-dose Part: Mean AUC(0-24h) postdose of perampanel on Day 1
Time Frame: 0-24 hours postdose on Day 1
0-24 hours postdose on Day 1
Multiple-dose Part: Mean value of area under the concentration-time curve over the dosing interval on multiple dosing (AUC[0-τ])
Time Frame: 0-24 hours postdose of perampanel on Day 21
0-24 hours postdose of perampanel on Day 21
Multiple-dose Part: Mean value of the average steady-state concentration (Css,av) postdose of perampanel on Day 21
Time Frame: 0-24 hours postdose on Day 21
0-24 hours postdose on Day 21
Multiple-dose Part: Mean value of the maximum observed concentration at steady state (Css,max) postdose of perampanel on Day 21
Time Frame: 0-24 hours postdose on Day 21
0-24 hours postdose on Day 21
Multiple-dose Part: Mean value of the minimum observed concentration at steady state (Css,min) postdose of perampanel on Day 21
Time Frame: 0-24 hours postdose on Day 21
0-24 hours postdose on Day 21
Multiple-dose Part: Mean value of peak-trough fluctuation (PTF) postdose of perampanel on Day 21
Time Frame: 0-24 hours postdose on Day 21
0-24 hours postdose on Day 21
Multiple-dose Part: Mean time at which the highest drug concentration occurs at steady state (tss,max) postdose of perampanel on Day 21
Time Frame: 0-24 hours postdose on Day 21
0-24 hours postdose on Day 21
Multiple-dose Part: Mean time at which the lowest drug concentration between dosing intervals occurs at steady state (tss,min) postdose of perampanel on Day 21
Time Frame: 0-24 hours postdose on Day 21
0-24 hours postdose on Day 21
Multiple-dose Part: Mean value of t1/2 postdose of perampanel on Day 21
Time Frame: 0-336 hours postdose on Day 21
0-336 hours postdose on Day 21
Multiple-dose Part: Mean value of apparent total clearance following oral administration at steady state (CLss/F) postdose of perampanel on Day 21
Time Frame: 0-24 hours postdose on Day 21
0-24 hours postdose on Day 21
Multiple-dose Part: Mean value of Vz/F postdose of perampanel on Day 21
Time Frame: 0-336 hours postdose on Day 21
0-336 hours postdose on Day 21
Multiple-dose Part: Mean value of the accumulation ratio
Time Frame: 0-24 hours postdose of perampanel on Days 1 and 21
0-24 hours postdose of perampanel on Days 1 and 21

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Eisai Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 20, 2018

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 25, 2018

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 25, 2018

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 1, 2018

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 1, 2018

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 7, 2018

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 28, 2018

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 27, 2018

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2018

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • E2007-C086-052

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Subjects

Clinical Trials on Perampanel

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings